Medtronic PLC (NYSE:MDT) – Analysts at Oppenheimer issued their Q1 2020 EPS estimates for shares of Medtronic in a research note issued to investors on Thursday, May 23rd, Zacks Investment Research reports. Oppenheimer analyst S. Lichtman expects that the medical technology company will earn $1.18 per share for the quarter. Oppenheimer has a “Buy” rating and a $104.00 price target on the stock. Oppenheimer also issued estimates for Medtronic’s Q2 2020 earnings at $1.28 EPS, Q3 2020 earnings at $1.37 EPS and Q4 2020 earnings at $1.63 EPS.
MDT has been the subject of several other research reports. Zacks Investment Research downgraded shares of Medtronic from a “hold” rating to a “sell” rating in a research note on Tuesday, April 30th. Wells Fargo & Co dropped their price objective on shares of Medtronic from $101.00 to $100.00 and set a “market perform” rating for the company in a research note on Thursday, April 4th. Northland Securities restated a “hold” rating and issued a $84.00 price target on shares of Medtronic in a research report on Monday, March 18th. Citigroup upped their price target on shares of Medtronic from $95.00 to $101.00 and gave the company a “neutral” rating in a research report on Monday, February 25th. Finally, Barclays restated a “buy” rating and issued a $104.00 price target on shares of Medtronic in a research report on Wednesday, February 20th. Eight analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $103.95.
NYSE:MDT traded up $0.64 on Monday, hitting $97.96. The company had a trading volume of 3,653,993 shares, compared to its average volume of 5,808,638. The company has a market cap of $131.23 billion, a price-to-earnings ratio of 18.77, a PEG ratio of 2.51 and a beta of 0.68. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.59 and a quick ratio of 2.15. Medtronic has a 52 week low of $81.66 and a 52 week high of $100.15.
Medtronic (NYSE:MDT) last issued its quarterly earnings results on Thursday, May 23rd. The medical technology company reported $1.54 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.47 by $0.07. Medtronic had a net margin of 15.15% and a return on equity of 14.16%. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.12 billion. During the same quarter in the prior year, the firm posted $1.42 EPS. The firm’s quarterly revenue was up .0% on a year-over-year basis.
In other news, EVP Hooman Hakami sold 52,664 shares of the stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $97.49, for a total transaction of $5,134,213.36. Following the completion of the sale, the executive vice president now directly owns 95,337 shares in the company, valued at $9,294,404.13. The transaction was disclosed in a filing with the SEC. Also, EVP Hoedt Rob Ten sold 9,000 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $91.88, for a total transaction of $826,920.00. Following the sale, the executive vice president now owns 58,785 shares of the company’s stock, valued at $5,401,165.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 72,664 shares of company stock valued at $7,017,683. 0.28% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of the business. WealthPLAN Partners LLC grew its holdings in Medtronic by 11.3% in the first quarter. WealthPLAN Partners LLC now owns 45,071 shares of the medical technology company’s stock worth $3,978,000 after purchasing an additional 4,585 shares during the period. Merit Financial Group LLC grew its holdings in Medtronic by 3.4% in the first quarter. Merit Financial Group LLC now owns 4,182 shares of the medical technology company’s stock worth $380,000 after purchasing an additional 136 shares during the period. Laurel Wealth Advisors Inc. acquired a new stake in Medtronic in the first quarter worth $214,000. M Holdings Securities Inc. grew its holdings in Medtronic by 3.6% in the first quarter. M Holdings Securities Inc. now owns 6,075 shares of the medical technology company’s stock worth $553,000 after purchasing an additional 211 shares during the period. Finally, Nordea Investment Management AB grew its holdings in Medtronic by 35.4% in the first quarter. Nordea Investment Management AB now owns 8,622,525 shares of the medical technology company’s stock worth $785,336,000 after purchasing an additional 2,255,412 shares during the period. Institutional investors and hedge funds own 80.03% of the company’s stock.
Medtronic Company Profile
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.